If you have read anything about epithalon (also spelled epitalon), you have read about telomeres. That single idea — a four-amino-acid peptide that switches telomerase back on — has carried the compound for twenty-five years. So it is worth noting that the most recent peer-reviewed epithalon research to land isn't about telomeres at all. It is about retinal cells in a dish, grown in high glucose, with a scratch drawn through them.

This post walks through what that 2025 paper actually tested, why it matters less than the headlines around epithalon suggest, and where the compound sits legally in Australia. If you want the background first, the epithalon profile covers the basics.

What is epithalon, and why the retina?

Epithalon is a synthetic tetrapeptide — alanine-glutamate-aspartate-glycine, hence "AEDG" — designed in the 1980s–90s to mimic the active fraction of Epithalamin, a bovine pineal gland extract. The two are not the same thing and shouldn't be used interchangeably, a distinction that gets flattened constantly in consumer write-ups.

The retina link is old, not new. The same St Petersburg group that created epithalon also created Retinalamin, a peptide preparation aimed at retinal disease, and published on epithalon in retinitis pigmentosa in Neuroendocrinology Letters in 2002, reporting improvement in most treated patients. That work was unblinded, uncontrolled and from the originating group — it generates a hypothesis, it does not test one. Two decades later, that hypothesis has finally been taken into a cell model.

The 2025 paper: high glucose, a scratch, and a tetrapeptide

Published in Stem Cell Reviews and Reports (online June 2025), the study used ARPE-19 cells — an immortalised human retinal pigment epithelial line — injured with high glucose to model the cellular environment of diabetic retinopathy.

What it showed

High glucose slowed wound closure in the scratch assay, pushed up intracellular reactive oxygen species, and lowered expression of antioxidant genes. It also drove epithelial-to-mesenchymal transition (EMT) and upregulated fibrosis-related genes — the cell-level process thought to underlie subretinal fibrosis in proliferative diabetic retinopathy. Adding epithalon restored wound closure, and the authors attribute that to suppression of the hyperglycaemia-induced EMT and fibrotic signalling rather than to any telomere effect.

What it does not show

It is one immortalised cell line, in vitro, with no animal arm and no human arm. A scratch assay measures how fast cells migrate across a gap in plastic — it is not vision, not retinal thickness, and not a clinical endpoint. Nothing in the paper speaks to whether injected epithalon reaches the human retina at a meaningful concentration, and nothing speaks to safety in eyes that are already diabetic. Treat it as a mechanism lead. It is also worth noting the irony: the finding is framed as antioxidant and anti-fibrotic, which is a different story from the telomerase one epithalon is sold on.

The independence problem hasn't gone away

The 2025 retina paper comes from an Italian group at Chieti, which reads like independent validation — until you check the author list, which includes Khavinson and colleagues from the originating group. That is a collaboration, not a replication.

The genuinely independent data point remains the 2025 Brunel University London work, the first detailed outside investigation of epithalon's telomere mechanism. It reported dose-dependent telomere lengthening in normal human cell lines via hTERT upregulation — and, in breast cancer lines, apparent telomere extension by an alternative lengthening pathway. That cancer-line result is an unresolved question, not a footnote, and the paper subsequently carried a published correction. Two 2025 papers, one collaborative and one independent, both in cells. That is the honest state of epithalon research: no approved indication anywhere, no regulator-grade human efficacy trial, and a literature still anchored to one research lineage.

Is epithalon legal in Australia, and where does the TGA sit?

Epithalon is not registered on the Australian Register of Therapeutic Goods and is not an approved medicine in Australia — or anywhere else. There is no TGA-evaluated product, no approved indication, and therefore no lawful way to advertise or supply it in Australia with therapeutic claims; doing so puts a seller squarely in unapproved-therapeutic-goods territory. Practically, anything marketed to Australians as an anti-ageing or eye-health epithalon product is being sold ahead of its evidence.

The diabetic retinopathy angle does have real local weight, which is exactly why claims need policing. Diabetes-related vision impairment is far more common among First Nations Australians — reported in the range of 5.2% to 26.5% across studies, against roughly 1.7% in non-Indigenous Australians — and blindness from end-stage retinopathy remains a live equity problem. Established options here (screening, glycaemic control, laser, intravitreal anti-VEGF) are supported by randomised trials. A tetrapeptide with one in-vitro paper is not in that conversation yet, and presenting it as an alternative to screening would be actively harmful.

What would actually move this forward

Three things, in order: a fully independent replication of the retinal effect with no originating-group authors; an animal model of diabetic retinopathy with functional outcomes rather than migration assays; and resolution of the cancer-cell telomere question before any human dosing study is contemplated. Until then, epithalon stays where it has sat for two decades — interesting, under-tested, and over-marketed. More compounds at the same stage are profiled across the peptides library, and you can join the free updates list to get new studies as they publish.

FAQ

What is epithalon used for?

Nothing approved. It is an investigational synthetic tetrapeptide (AEDG) studied mainly in cells and animals for telomerase activation, circadian and pineal effects, and most recently antioxidant/anti-fibrotic effects in retinal cells.

Does epithalon help the eyes or retina?

A 2025 in-vitro study found epithalon restored delayed wound closure in high-glucose-injured human retinal pigment epithelial cells. That is a cell-line result in a dish, not evidence of benefit to human vision.

Is epithalon legal in Australia?

Epithalon is not on the ARTG and is not an approved medicine in Australia. It cannot lawfully be advertised or supplied to Australians with therapeutic claims.

Has epithalon been tested in humans?

Only in small, mostly unblinded studies from the single Russian group that developed it, including a 2002 retinitis pigmentosa report. No independent, regulator-grade human efficacy trial has been published.

Sources

This article is information only, not medical advice, and retatrutide.net.au is independent and not affiliated with any manufacturer or supplier. Epithalon (epitalon) is not an approved medicine in Australia or anywhere else and remains investigational; discuss any health decision with a qualified Australian health practitioner.